(Q37852818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Treatment strategies for dosing the second generation antipsychotics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

2

Stephen M Stahl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Thomas L Schwartz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

110-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

Dosing of Second-Generation Antipsychotic Medication in a State Hospital System

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Optimal dosing of atypical antipsychotics in adults: a review of the current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Switching between second-generation antipsychotics: why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

The role of 5-HT2A receptors in antipsychotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Risperidone in the treatment of acute mania: double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Efficacy of olanzapine in social anxiety disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Obesity, serious mental illness and antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Management of schizophrenia with obesity, metabolic, and endocrinological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

An evaluation of monitoring practices in patients on second generation antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Datapoints: The Ups and Downs of Dosing Second-Generation Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Buspirone-induced changes in the serotonergic and non-serotonergic cells in the dorsal raphe nucleus of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Ziprasidone monotherapy in bipolar II depression: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Ziprasidone in the treatment of affective disorders: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Open-label pilot study of ziprasidone for refractory generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Aripiprazole in schizophrenia and schizoaffective disorder: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Iloperidone: a new option for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

Multifunctional drugs: a novel concept for psychopharmacology

21 January 2018

2 references

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2011.00234.X

21 January 2018

12 December 2020

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice

1 reference

12 December 2020

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

12 December 2020

Atypical antipsychotics: matching receptor profile to individual patient's clinical profile

1 reference

12 December 2020

Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.

1 reference

12 December 2020

A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression

1 reference

12 December 2020

Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study

1 reference

12 December 2020

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

1 reference

12 December 2020

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

1 reference

12 December 2020

Dosing atypical antipsychotics

1 reference

12 December 2020

Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.

1 reference

12 December 2020

Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study

1 reference

12 December 2020

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.

1 reference

12 December 2020

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

1 reference

12 December 2020

Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder.

1 reference

12 December 2020

How dosing of ziprasidone in a state hospital system differs from product labeling.

1 reference

12 December 2020

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

10.1111/J.1755-5949.2011.00234.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401911%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

PubMed publication ID

21401911

1 reference